Navigation Links
Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement
Date:9/17/2010

PHOENIX, Sept. 17 /PRNewswire/ -- Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.

The Center for Healthcare Innovation & Clinical Trials (https://nursingandhealth.asu.edu/clinical-trials).at ASU – part of the College of Nursing & Health Innovation – is only the fifth organization in the world to become a global prime site partner for Quintiles.

Through Quintiles the Center will receive access to many more clinical research initiatives. In return, the Center will deploy its unique community-based model to recruit more physicians and nurse practitioners who can identify patients who are willing and eligible to participate in the research.

Access to patients to participate in clinical trials is one of the major barriers to bringing much needed safe and effective drugs to market faster and with less cost.

Linda Mottle, Director of the Center for Healthcare Innovation & Clinical Trials at ASU, noted that the clinical research market in Arizona lags other states with comparable population sizes and explained: "We believe our community-based model can substantially increase the clinical research market in Arizona."

Adam Chasse, Senior Director for Patient Access at Quintiles, added: "Access to patients is one of the toughest hurdles in working with our biopharmaceutical customers to accelerate outcomes and get better value from the drug development process.  This agreement with ASU will help our customers to meet study milestones more effectively by providing access to large groups of physicians, known as 'investigators,' who are interested in participating in clinical research and who treat large groups of patients."

The ASU center is the only one of Quintiles' five global prime sites that is a community-based, non-academic medical center. ASU's model, the Community Oriented Network to Enhance Clinical Trials and Research (CONECTR), will serve as the hub for placing, subcontracting, consulting and supporting multi-phased research studies within Arizona.

Ken Levin, Chief Executive Officer of Precision Trials and a member of the Center Advisory Board, sees CONECTR providing multiple benefits for community research organizations:  "By offering assistance and support to providers, CONECTR will increase the number of qualified investigators and sites conducting research in Arizona. The program aligns clinical research pipeline opportunities with local investigators by their capability."

Quintiles' other prime site partners are Kaiser Permanente in Southern California, the University of Pretoria in South Africa, Queen Mary's College in London, Washington Hospital Center in Washington, D.C., and the University of Malaya in Malaysia.


'/>"/>
SOURCE Arizona State University College of Nursing & Health Innovation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
2. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
3. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
4. Zero Discharge Sweet Sorghum Ethanol Process Development
5. NASA funds development of nanoscale materials for high energy density lithium-ion batteries
6. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
7. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
8. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
11. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):